Medical and psychiatric comorbidities: Complicating treatment expectations

Brian J Miller, Peter F Buckley

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Upon all outcomes, premature mortality is a profound consequence of medical and psychiatric (especially depression with suicidality) comorbidities. Additionally, obesity and metabolic disturbances substantially complicate the selection and duration of trial of subsequent antipsychotic medications. This is most pronounced with respect to clozapine, wherein obesity and metabolic dysfunction now predominate and powerful influence the use of this drug as well as adjunctive therapies.

Original languageEnglish (US)
Title of host publicationTreatment-Refractory Schizophrenia
Subtitle of host publicationA Clinical Conundrum
PublisherSpringer Berlin Heidelberg
Pages45-64
Number of pages20
ISBN (Electronic)9783642452574
ISBN (Print)9783642452567
DOIs
StatePublished - Jan 1 2014

Fingerprint

Psychiatry
Comorbidity
Obesity
Premature Mortality
Clozapine
Antipsychotic Agents
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Miller, B. J., & Buckley, P. F. (2014). Medical and psychiatric comorbidities: Complicating treatment expectations. In Treatment-Refractory Schizophrenia: A Clinical Conundrum (pp. 45-64). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-45257-4_4

Medical and psychiatric comorbidities : Complicating treatment expectations. / Miller, Brian J; Buckley, Peter F.

Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, 2014. p. 45-64.

Research output: Chapter in Book/Report/Conference proceedingChapter

Miller, BJ & Buckley, PF 2014, Medical and psychiatric comorbidities: Complicating treatment expectations. in Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, pp. 45-64. https://doi.org/10.1007/978-3-642-45257-4_4
Miller BJ, Buckley PF. Medical and psychiatric comorbidities: Complicating treatment expectations. In Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg. 2014. p. 45-64 https://doi.org/10.1007/978-3-642-45257-4_4
Miller, Brian J ; Buckley, Peter F. / Medical and psychiatric comorbidities : Complicating treatment expectations. Treatment-Refractory Schizophrenia: A Clinical Conundrum. Springer Berlin Heidelberg, 2014. pp. 45-64
@inbook{f407f48b495d4de69dd18823bc59dc4a,
title = "Medical and psychiatric comorbidities: Complicating treatment expectations",
abstract = "Upon all outcomes, premature mortality is a profound consequence of medical and psychiatric (especially depression with suicidality) comorbidities. Additionally, obesity and metabolic disturbances substantially complicate the selection and duration of trial of subsequent antipsychotic medications. This is most pronounced with respect to clozapine, wherein obesity and metabolic dysfunction now predominate and powerful influence the use of this drug as well as adjunctive therapies.",
author = "Miller, {Brian J} and Buckley, {Peter F}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-642-45257-4_4",
language = "English (US)",
isbn = "9783642452567",
pages = "45--64",
booktitle = "Treatment-Refractory Schizophrenia",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Medical and psychiatric comorbidities

T2 - Complicating treatment expectations

AU - Miller, Brian J

AU - Buckley, Peter F

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Upon all outcomes, premature mortality is a profound consequence of medical and psychiatric (especially depression with suicidality) comorbidities. Additionally, obesity and metabolic disturbances substantially complicate the selection and duration of trial of subsequent antipsychotic medications. This is most pronounced with respect to clozapine, wherein obesity and metabolic dysfunction now predominate and powerful influence the use of this drug as well as adjunctive therapies.

AB - Upon all outcomes, premature mortality is a profound consequence of medical and psychiatric (especially depression with suicidality) comorbidities. Additionally, obesity and metabolic disturbances substantially complicate the selection and duration of trial of subsequent antipsychotic medications. This is most pronounced with respect to clozapine, wherein obesity and metabolic dysfunction now predominate and powerful influence the use of this drug as well as adjunctive therapies.

UR - http://www.scopus.com/inward/record.url?scp=84956773193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956773193&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-45257-4_4

DO - 10.1007/978-3-642-45257-4_4

M3 - Chapter

AN - SCOPUS:84956773193

SN - 9783642452567

SP - 45

EP - 64

BT - Treatment-Refractory Schizophrenia

PB - Springer Berlin Heidelberg

ER -